Genetic predispositions to low-grade inflammation and type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 8, Issue 1, 2006, Pages 55-66

  Fernández Real, Jose Manuel ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADIPONECTIN; CYTOKINE; INSULIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROTEIN; SOLUBLE CD4 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURVIVAL TIME; TISSUE REPAIR;

DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; INFLAMMATION; METABOLIC SYNDROME X; MUTATION; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645307126     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.8.55     Document Type: Conference Paper

References (94)

1. Beutler B: Innate immunity: an overview. Mol Immunol 2004;40:845-859.
2. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
3. Munford RS: Statins and the acute phase response. N Engl J Med 2001;344:2016-2018.
4. Pickup JC, Crook MA: Is type II diabetes a disease of the innate immune system? Diabetologia 1998;41:1241-1248.
5. Fernández-Real JM, Ricart W: Insulin resistance and inflammation in an evolutionary perspective. The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999;42:1367-1374.
6. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
7. Fernández-Real JM, Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
8. Kahaleh MB, Fan PS: Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol 1997;15:163-167.
9. Brasier AR, Li J, Wimbish KA: Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996;27:1009-1017.
10. Pausova Z, Deslauriers B, Gaudet D, Tremblay J, Kotchen TA, Larochelle P, Cowley AW, Hamet P: Role of tumor necrosis factor-α gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension 2000;36:14-19.
11. Fernández-Real JM, Vayreda M, Richart C, Gutiérrez C, Broch M, Vendrell J, Ricart W: Circulating interleukin 6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-1159.
12. Straub RH, Hense HW, Andus J, Schölmerich J, Riegger AJ, Schunkert H: Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000;85:1340-1344.
13. Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
14. Pola R, Flex A, Gaetani E, Pola P, Bernabei R: The -174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population. J Hum Hypertens 2002;16:637-640.
15. Losito A, Kalidas K, Santoni S, Jeffery S: Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003;64:616-622.
16. Fantuzzi G, Faggioni R: Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000;68:437-446.
17. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105:1243-1252.
18. Wybranska I, Malczewska-Malec M, Niedbal S, Naskalski JW, Dembinska-Kiec A: The TNF-alpha gene NcoI polymorphism at position -308 of the promoter influences insulin resistance, and increases serum triglycerides after postprandial lipaemia in familiar obesity. Clin Chem Lab Med 2003;41:501-510.
19. Markovic O, O'Reilly G, Fussell HM, Turner SJ, Calder PC, Howell WM, Grimble RF: Role of single nucleotide polymorphisms of pro-inflammatory cytokine genes in the relationship between serum lipids and inflammatory parameters, and the lipid-lowering effect of fish oil in healthy males. Clin Nutr 2004;23:1084-1095.
20. Benjafield AV, Glenn CL, Wang XL, Colagiuri S, Morris BJ: TNFRSF1B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes. Diabetes Care 2001;24:753-757.
21. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W: Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000;85:1334-1339.
22. Lieb W, Pavlik R, Erdmann J, Mayer B, Holmer SR, Fischer M, Baessler A, Hengstenberg C, Loewel H, Doering A, Riegger GA, Schunkert H: No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004;97:205-212.
23. Corbalan MS, Marti A, Forga L, Patino A, Martinez-Gonzalez MA, Martinez JA: Influence of two polymorphisms of the tumoral necrosis factor-alpha gene on the obesity phenotype. Diabetes Nutr Metab 2004;17:17-22.
24. Hoffstedt J, Eriksson P, Hellstrom L, Rossner S, Ryden M, Arner P: Excessive fat accumulation is associated with the TNF alpha-308 G/A promoter polymorphism in women but not in men. Diabetologia 2000;43:117-120.
25. Um JY, Kang BK, Lee SH, Shin JY, Hong SH, Kim HM: Polymorphism of the tumor necrosis factor alpha gene and waist-hip ratio in obese Korean women. Mol Cell 2004;18:340-345.
26. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
27. Fernández-Real JM, Gutierrez C, Ricart W, Casamitjana R, Vendrell J, Fernández-Castañer M, Richart C, Soler J: The TNF-α Nco I polymorphism influences the relationship among insulin resistance, percent body fat and increased serum leptin levels. Diabetes 1997;46:1468-1472.
28. Skoog T, Eriksson P, Hoffstedt J, Rydén M, Hamsten A, Arner P: Tumour necrosis factor-α (TNF-α) polymorphisms -857C/A and -863C/A are associated with TNF-α secretion from human adipose tissue. Diabetologia 2001;44:654-655.
29. Schreyer SA, Chua SC, LeBoeuf RC: Obesity and diabetes in TNF-alpha receptor-deficient mice. J Clin Invest 1998;102:402-411.
30. Fernández-Real JM, Vendrell J, Ricart W, Broch M, Gutiérrez C, Casamitjana R, Oriola J, Richart C: A polymorphism of the tumor necrosis factor receptor-2 gene is associated with obesity, leptin levels and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000;23:831-837.
31. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79.
32. Fernández-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interleukin 6 and insulin sensitivity. Diabetes 2000;49:517-520.
33. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG: Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-1092.
34. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281-312.
35. Stephens JM, Butts MD, Pekala PH: Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol 1992;9:61-72.
36. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
37. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
38. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D: Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002;87:3864-3866.
39. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-1804.
40. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL: Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806-811.
41. Bosch M, López-Bermejo A, Musri M, Vendrell J, Ricart W, Fernández-Real JM: Circulating interleukin-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia 2005;48:1841-1843.
42. Vendrell J, Gutierrez C, Pastor R, Richart C: A tumor necrosis factor-beta polymorphism associated with hypertriglyceridemia in non-insulin-dependent diabetes mellitus. Metab Clin Exp 1995;44:691-694.
43. Kankova K, Marova I, Jansen EHJM, Vasku A, Jurajda M, Vacha J: Polymorphism NcoI in tumor necrosis factor beta is associated with fasting glycemia and lipid parameters in healthy non-obese Caucasian subjects. Diabetes Metab 2002;28:231-237.
44. Fernandez-Real JM, Gutierrez C, Ricart W, Casamitjana R, Broch M, Vendrell J, Richart C: The TNF-β gene NcoI polymorphism is not associated with hypertriglyceridemia or insulin resistance in lean and obese subjects. Biochem Biophys Res Commun 1997;236:829-832.
45. Hamid YH, Urhammer SA, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O: The common T60N polymorphism of the lymphotoxin-alpha gene is associated with type 2 diabetes and other pheno-types of the metabolic syndrome. Diabetologia 2005;48:445-451.
46. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P: Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003;12:805-816.
47. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-3108.
48. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-1525.
49. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-192.
50. Illig T, Bongardt F, Schopfer A, Holle R, Muller S, Rathmann W, Koenig W, Meisinger C, Wichmann HE, Kolb H; KORA Study Group: The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 2003;52:2861-2864.
51. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Home BD, Bair TL, Anderson JL: Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reauctions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004;148:1034-1040.
52. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W: A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999;19:932-938.
53. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, Schmitz G: C (-260)- T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999;99:3218-3220.
54. Ito D, Murata M, Tanahashi N, Sato H, Sonoda A, Saito I, Watanabe K, Fukuuchi Y: Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 2000;31:2661-2664.
55. Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H: Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000;86:682-684.
56. Fernandez-Real JM, Broch M, Richart C, Vendrell J, Lopez-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003;88:1780-1784.
57. Eilertsen KE, Olsen JO, Brox J, Osterud B: Association of the -159 C → T polymorphism in the CD14 promoter with variations in serum lipoproteins in healthy subjects. Blood Coagul Fibrinolysis 2003;14:663-670.
58. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E: Characterisation of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739-743.
59. Robey FA, Liu T-Y: Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem 1981;256:969-975.
60. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S: Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005;25:1051-1056.
61. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Tataranni P, Bogardus C, Hanson RL: A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003;78:136-144.
62. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013-3020.
63. Summerfield JA, Sumiya M, Levin M, Turner MW: Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-1232.
64. Best LG, Davidson M, North KE, MacCluer JW, Zhang Y, Lee ET, Howard BV, DeCroo S, Ferrell RE: Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004;109:471-475.
65. Megia A, Gallart L, Fernández-Real JM, Vendrell J, Simón I, Gutiérrez C, Richart C: Mannose-binding lectin gene polymorphism are associated with gestational diabetes mellitus. J Clin Endocrinol Metab 2004;89:5081-5087.
66. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
67. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
68. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
69. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y: Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003;88:3236-3240.
70. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231-234.
71. Fernandez-Real JM, Castro A, Vazquez G, Casamitjana R, Lopez-Bermejo A, Penarroja G, Ricart W: Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004;27:739-745.
72. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-1881.
73. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
74. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-2010.
75. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin. Nat Med 2002;8:731-737.
76. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
77. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
78. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
79. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
80. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-16313.
81. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536-540.
82. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, Machicao F, Haring H: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002;51:37-41.
83. Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, Trischitta V, Doria A: A haplo-type at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51:2306-2312.
84. Berthier MT, Houde A, Cote M, Paradis AM, Mauriege P, Bergeron J, Gaudet D, Despres JP, Vohl MC: Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J Lipid Res 2005;46:237-244.
85. Vionnet N, Hani El H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genome-wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470-1480.
86. Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, Lecoeur C, Vatin V, Durand E, Hara K, Okada T, Tobe K, Boutin P, Kadowaki T, Froguel P: Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 2002;51:1247-1255.
87. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97:14478-14483.
88. Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, Foroud T, Kobes S, Baier L, Burns DK, Almasy L, Blangero J, Garvey WT, Bennett PH, Knowler WC: An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet 1998;63:1130-1138.
89. Pratley RE, Thompson DB, Prochazka M, Baier L, Mott D, Ravussin E, Sakul H, Ehm MG, Burns DK, Foroud T, Garvey WT, Hanson RL, Knowler WC, Bennett PH, Bogardus C: An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest 1998;101:1757-1764.
90. Vozarova de Courten B, Hanson RL, Funahashi T, Lindsay RS, Matsuzawa Y, Tanaka S, Thameem F, Gruber JD, Froguel P, Wolford JK: Common polymorphisms in the adiponectin gene ACDC are not associated with diabetes in Pima Indians. Diabetes 2005;54:284-289.
91. Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, Park HJ, Youn BS, Lee HK, Park KS, Shin HD: Genetic association study of adiponectin polymorphisms with risk of Type 2 diabetes mellitus in Korean population. Diabet Med 2005;22:569-575.
92. Recasens M, López-Bermejo A, Ricart W, Vendrell J, Casamitjana R, Fernández-Real JM: An inflammation score is better associated with basal than with stimulated indexes of insulin resistance. J Clin Endocrinol Metab 2005;90:112-116.
93. Lev-Ran A: Thrifty genotype: how applicable is it to obesity and type 2 diabetes? Diabetes Rev 1999;7:1-22.
94. Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK: The interleukin-6 (-174) G/C promoter polymorphism is associated with type 2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003;112:409-413.